Thomas R. Parr, Jr., Ph.D.
Chief Scientific Officer

Thomas R. Parr, Jr., Ph.D. has served as Chief Scientific Officer of Targanta since January 2005. From May 2003 to December 2004, Dr. Parr was Vice President of Research at Adaptive Therapeutics. From May 2002 to May 2003, Dr. Parr served in various capacities at Embiosis Pharmaceuticals, formerly MicroGenomics, Inc., most recently as its President and acting Chief Executive Officer. From August 2001 to March 2002, Dr. Parr was Senior Director of Microbiology at Xenogen Corporation, a private biopharmaceutical company and from May 2000 to August 2001, Dr. Parr was Senior Director of Microbiology at Intrabiotics Pharmaceuticals, Inc. From 1997 to 2000, Dr. Parr was a Microbiologist at Lilly, ending his tenure there as Senior Research Scientist.

During his career, Dr. Parr has been involved in the development of several marketed and late-stage clinical candidates for both antibacterial and antifungal applications. Dr. Parr received a Ph.D. degree in Microbiology and Infectious Diseases from The University of Calgary, an M.A. in Philosophy from the University of Calgary and a B.A. in Biology and Philosophy from the University of Minnesota. He was a postdoctoral fellow at The University of British Columbia, and a member of the faculty at The University of Ottawa before beginning his industrial career.